Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience.

2.50
Hdl Handle:
http://hdl.handle.net/10146/64976
Title:
Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience.
Authors:
Fujimura, Takashi; Ohta, Tetsuo; Oyama, Katsunobu; Miyashita, Tomoharu; Miwa, Koichi
Abstract:
Selective cyclooxygenase (COX)-2 inhibitors (coxibs) were developed as one of the anti-inflammatory drugs to avoid the various side effects of non-steroidal anti-inflammatory drugs (NSAIDs). However,coxibs also have an ability to inhibit tumor development of various kinds the same way that NSAIDs do. Many experimental studies using cell lines and animal models demonstrated an ability to prevent tumor proliferation of COX-2 inhibitors. After performing a randomized study for polyp chemoprevention study in patients with familial adenomatous polyposis (FAP),which showed that the treatment with celecoxib, one of the coxibs, significantly reduced the number of colorectal polyps in 2000, the U.S. Food and Drug Administration (FDA) immediately approved the clinical use of celecoxib for FAP patients. However, some coxibs were recently reported to increase the risk of serious cardiovascular events including heart attack and stroke. In this article we review a role of COX-2 in carcinogenesis of gastrointestinal tract, such as the esophagus, stomach and colorectum,and also analyze the prospect of coxibs for chemoprevention of gastrointestinal tract tumors.
Citation:
World J. Gastroenterol. 2006, 12 (9):1336-1345
Journal:
World journal of gastroenterology : WJG
Issue Date:
7-Mar-2006
URI:
http://hdl.handle.net/10146/64976
PubMed ID:
16552798
Additional Links:
http://www.wjgnet.com/1007-9327/12/1336.asp
Type:
Article
Language:
en
Description:
KEYWORDS CLASSIFICATION: adverse effects;analysis;Adenomatous Polyposis Coli;chemically induced;chemistry;Cardiovascular Diseases;Cell Proliferation;Colorectal Neoplasms;Cyclooxygenase 2;Cyclooxygenase 2 Inhibitors;drug effects;drug therapy;Dinoprostone;etiology;Esophageal Neoplasms;Food;genetics;Gastrointestinal Neoplasms;Humans;Intestinal Mucosa;Japan;metabolism;mechanisms of carcinogenesis;pharmacology;physiology;physiopathology;prevention & control;Risk Factors;RNA,Messenger;Stomach Neoplasms;therapeutic use.
ISSN:
1007-9327
Appears in Collections:
Articles with annotation

Full metadata record

DC FieldValue Language
dc.contributor.authorFujimura, Takashi-
dc.contributor.authorOhta, Tetsuo-
dc.contributor.authorOyama, Katsunobu-
dc.contributor.authorMiyashita, Tomoharu-
dc.contributor.authorMiwa, Koichi-
dc.date.accessioned2009-04-15T12:00:35Z-
dc.date.available2009-04-15T12:00:35Z-
dc.date.issued2006-03-07-
dc.identifier.citationWorld J. Gastroenterol. 2006, 12 (9):1336-1345en
dc.identifier.issn1007-9327-
dc.identifier.pmid16552798-
dc.identifier.urihttp://hdl.handle.net/10146/64976-
dc.descriptionKEYWORDS CLASSIFICATION: adverse effects;analysis;Adenomatous Polyposis Coli;chemically induced;chemistry;Cardiovascular Diseases;Cell Proliferation;Colorectal Neoplasms;Cyclooxygenase 2;Cyclooxygenase 2 Inhibitors;drug effects;drug therapy;Dinoprostone;etiology;Esophageal Neoplasms;Food;genetics;Gastrointestinal Neoplasms;Humans;Intestinal Mucosa;Japan;metabolism;mechanisms of carcinogenesis;pharmacology;physiology;physiopathology;prevention & control;Risk Factors;RNA,Messenger;Stomach Neoplasms;therapeutic use.en
dc.description.abstractSelective cyclooxygenase (COX)-2 inhibitors (coxibs) were developed as one of the anti-inflammatory drugs to avoid the various side effects of non-steroidal anti-inflammatory drugs (NSAIDs). However,coxibs also have an ability to inhibit tumor development of various kinds the same way that NSAIDs do. Many experimental studies using cell lines and animal models demonstrated an ability to prevent tumor proliferation of COX-2 inhibitors. After performing a randomized study for polyp chemoprevention study in patients with familial adenomatous polyposis (FAP),which showed that the treatment with celecoxib, one of the coxibs, significantly reduced the number of colorectal polyps in 2000, the U.S. Food and Drug Administration (FDA) immediately approved the clinical use of celecoxib for FAP patients. However, some coxibs were recently reported to increase the risk of serious cardiovascular events including heart attack and stroke. In this article we review a role of COX-2 in carcinogenesis of gastrointestinal tract, such as the esophagus, stomach and colorectum,and also analyze the prospect of coxibs for chemoprevention of gastrointestinal tract tumors.en
dc.language.isoenen
dc.relation.urlhttp://www.wjgnet.com/1007-9327/12/1336.aspen
dc.subjectCyclooxygenase-2 (COX-2)en
dc.subjectSelective COX-2 inhibitorsen
dc.subjectEsophageal canceren
dc.subjectGastric canceren
dc.subjectColorectal canceren
dc.subject.meshAdenomatous Polyposis Coli-
dc.subject.meshCardiovascular Diseases-
dc.subject.meshCell Proliferation-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshCyclooxygenase 2-
dc.subject.meshCyclooxygenase 2 Inhibitors-
dc.subject.meshDinoprostone-
dc.subject.meshEsophageal Neoplasms-
dc.subject.meshGastrointestinal Neoplasms-
dc.subject.meshHumans-
dc.subject.meshIntestinal Mucosa-
dc.subject.meshRNA, Messenger-
dc.subject.meshRisk Factors-
dc.subject.meshStomach Neoplasms-
dc.titleRole of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience.en
dc.typeArticleen
dc.identifier.journalWorld journal of gastroenterology : WJGen

Related articles on PubMed

All Items in ECNIS-NIOM are protected by copyright, with all rights reserved, unless otherwise indicated.